PharmiWeb.com - Global Pharma News & Resources
06-Nov-2020 - 06-Nov-2020

BERGENBIO VIRTUAL R&D DAY – 06 NOVEMBER 2020

Bergen, Norway, 23rd October 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce that it will host a virtual R&D Day on 06 November 2020 from 13.00 CET.

The event will feature independent experts, highlighting the role of AXL kinase as an essential mediator of the biological mechanisms underlying life-threatening diseases. The presentations will focus on the role of AXL in specific disease areas including oncology, fibrosis and infectious disease such as COVID-19. Each presentation will be followed by a Q&A session.

A preliminary program for the event is outlined below. To register, please click here.

 

 

Preliminary Agenda
(times in CET)